U.S. FDA Extended Approval For Merck & Co., Inc.’s Steglujan (ertugliflozin and sitagliptin) Tablets For The Treatment Of Type 2 Diabetes

U.S. FDA approved Merck & Co., Inc.’s Steglujan Tablets for the treatment of Type 2 Diabetes

 

U.S. FDA (Food and Drug Administration) recently approved Merck & Co., Inc.’s Steglujan (ertugliflozin and sitagliptin) Tablets for the treatment of Type 2 Diabetes

Company: Merck & Co., Inc.

Brand Name:  Steglujan

Treatment for:  Diabetes Type 2

Dosage Form: Tablets

Generic name: ertugliflozin and sitagliptin

 

 

General information about Balcoltra

Steglujan (ertugliflozin and sitagliptin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor, and dipeptidyl peptidase-4 (DPP-4) inhibitor combination used to improve glycemic control in adults with type 2 diabetes.

Steglujan is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate. Steglujan is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. 

Top